Table 1.
Demographic and clinical characteristics of enrolled subjects
| Total sample | NTZ treatment interval | ||||
|---|---|---|---|---|---|
| 4 weeks | 5 weeks | 6 weeks | p value | ||
| N (%) | 86 | 16 (18.6%) | 23 (26.7%) | 47 (54.6%) | |
| Mean (SD) age (years) | 40.3 (10.1) | 37.2 (12.5) | 41.7 (9.3) | 40.7 (9.7) | 0.371 |
| Sex F/M (%) | 62/24 (71.2/28.8) | 12/4 (75.0/25.0) | 17/6 (73.9/26.1) | 33/14 (68.7/31.3) | |
| Mean (SD) BMI | 25.5 (5.2) | 25.8 (5.8) | 24.2 (3.5) | 26.1 (5.6) | 0.355 |
| Mean (SD) disease duration (months) | 183.0 (94.1) | 124.5 (78.7) | 207.4 (115.0) | 190.2 (83.5) | < 0.001 |
| Mean (SD) treatment duration with NTZ (months) | 80.5 (40.2) | 31.4 (9.4) | 84.1 (43.1) | 95.4 (31.6) | 0.036 |
| Mean EDSS | 3.3 (1.5) | 2.8 (1.2) | 3.5 (1.7) | 3.5 (1.6) | 0.303 |
NTZ natalizumab, BMI body mass index, EDSS Expanded Disability Status Scale
Bolditalics for significant values, italics for non significant p values